In addition, we also observed that high mRNA expression of AnxA2 was significantly associated with worse diseases specific survival (DSS; hazard ratio = 1.562; 95% CI = 1.085−2.249; log-rank p = 0.0165; Figure 2B) and worse progression-free survival (PFS; hazard ratio = 1.433; 95% CI = 1.06−1.937; log-rank p = 0.0193; Figure 2C) in BLCA patients. This evidence concerns the gene ANXA2 and bladder transitional cell carcinoma.